Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tolerability, adherence and efficacy of single
tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with
a history of injection drug use (IDU) switching from existing antiretroviral therapy (ART) or
starting treatment after discontinuation of ART.
Phase:
Phase 4
Details
Lead Sponsor:
University College Dublin
Collaborators:
Mater Misericordiae University Hospital ViiV Healthcare